{"id":"W4410068839","doi":"10.1002/ejhf.3673","title":"Pathophysiology and Clinical Use of Agents with Vasodilator Properties in Acute Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","year":2025,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Surgical Specialties (Canada)","funders":"Respicardia; Abbott Vascular; Servier; Chugai Pharmaceutical; Sphingotec GmbH; Vifor Pharma; Schweizerische Herzstiftung; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Idorsia Pharmaceuticals; Impulse Dynamics; Novo Nordisk; Abbott Laboratories; National Institute for Health and Care Research; ReCor Medical; Astellas Pharma; Cytokinetics; Boston Scientific Corporation; Patient-Centered Outcomes Research Institute; Universität Basel; Singulex; Amgen; Edwards Lifesciences; Alnylam Pharmaceuticals; AstraZeneca; Kowa Company; U.S. Department of Defense; Sanofi; National Institutes of Health; Regeneron Pharmaceuticals; Pfizer; Les Laboratories Pierre Fabre; National Science Foundation","keywords":"Medicine; Heart failure; Vasodilation; Nesiritide; Afterload; Preload; Cardiology; Internal medicine; Decompensation; Intensive care medicine; Hemodynamics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003675139,0.0008471375,0.001601859,0.001275999,0.0005816169,0.002944607,0.001207986,0.00305766,0.002089332],"category_scores_gemma":[0.004654482,0.0003710722,0.001210452,0.0007576668,0.001608369,0.001777707,0.001126882,0.003324483,0.001120223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00121318,"about_ca_system_score_gemma":0.001474099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005685718,"about_ca_topic_score_gemma":0.0005587786,"domain_scores_codex":[0.9975882,0.0009580813,0.0003257694,0.0003155406,0.0006146219,0.0001979733],"domain_scores_gemma":[0.9966778,0.001099633,0.001002803,0.0001701338,0.0006336555,0.0004161228],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003762671,0.001882741,0.03409015,0.01529521,0.001126465,0.004915859,0.001315509,0.001235767,0.02545447,0.09357978,0.05812604,0.7592153],"study_design_scores_gemma":[0.001990512,0.01012313,0.08535507,0.01077552,0.001803358,0.02656201,0.0009476406,0.00457827,0.01431609,0.0745129,0.7687553,0.000280225],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01405068,0.9409747,0.004305686,0.02659073,0.001976311,0.0001927792,0.0002793733,0.00007047076,0.01155922],"genre_scores_gemma":[0.2197308,0.7297856,0.009987501,0.01908144,0.01483934,0.0007306755,0.0006017048,0.00005821137,0.005184747],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003675139,"threshold_uncertainty_score":0.01943618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05352921350119626,"score_gpt":0.3110315324551698,"score_spread":0.2575023189539735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}